
Market Cap
$189.56B
P/E Ratio
35.45
52W High
$137.49
52W Low
$81.97
Quality Score
ABT scores 67/100 (C) — dividend safety is the strongest factor, momentum the weakest.
67
/ 100
See the full 7-factor breakdown with PRO.
UpgradeAI Technical Interpretation
PRO turns ABT's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.
Upgrade to PROAI “Why Did It Move?”
Get a ranked, evidence-grounded read on what's likely driving ABT's move today — news, earnings, analyst activity, sector context, and technicals combined.
Upgrade to PROAnalyst Ratings27 analysts
Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.
AI Fair Value Estimate
Get an AI analyst's take on whether ABT looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.
Upgrade to PROAI Earnings Preview
Next report 2026-10-14 · in 43 days
Consensus estimates
EPS
$1.42
Revenue
$12.99B
Recent EPS surprises
Unlock the AI preview for ABT
Get an AI analyst's read on the setup, what to watch, and risks heading into the print.
Upgrade to PROUnlock the post-earnings recap for ABT
Get an AI analyst's read on how the report went and how the stock reacted.
Upgrade to PRODividendQuarterly
Forward yield
2.30%
Annual / share
$2.52
Last ex-date
Jul 15, 2026
Last payment
Aug 17, 2026
Recent payments
Forward annual dividend from the declared rate (or latest payment × frequency) · via Yahoo Finance & Financial Modeling Prep.
AI Dividend Safety
Get an AI read on whether ABT's dividend looks sustainable — earnings coverage, payout history, and the risks worth researching.
Upgrade to PROInsider Trading50 recent filings
Buys
31
Sells
19
Reported value
$12.16M
| Date | Insider | Type | Shares | Price | Value | Owned |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | MORRONE, LOUIS H. EXECUTIVE VICE PRESIDENT | Sell | 12 | $107.99 | $1,295.88 | - |
| Aug 11, 2026 | MORRONE, LOUIS H. EXECUTIVE VICE PRESIDENT | Sell | 5,850 | $109.83 | $642,505.50 | - |
| Jun 30, 2026 | CONROY, KEVIN T Director | Buy | 231 | $90.74 | $20,960.94 | - |
| Jun 30, 2026 | GONZALEZ, PATRICIA PAOLA Director | Buy | 363 | $90.74 | $32,938.62 | - |
| Jun 30, 2026 | ROMAN, MICHAEL F Director | Buy | 416 | $90.74 | $37,747.84 | - |
| Jun 30, 2026 | STRATTON, JOHN G Director | Buy | 432 | $90.74 | $39,199.68 | - |
| Jun 30, 2026 | MORRONE, LOUIS H. EXECUTIVE VICE PRESIDENT | Sell | 269 | $92.71 | $24,938.99 | - |
| Jun 30, 2026 | AHUJA, NITA Director | Buy | 347 | $90.74 | $31,486.78 | - |
| Jun 27, 2026 | CUSHMAN, ELIZABETH C. EVP, GC AND SECRETARY | Sell | 560 | $94.12 | $52,707.20 | - |
| May 7, 2026 | STRATTON, JOHN G Director | Buy | 2,000 | $86.82 | $173,640.00 | - |
| Apr 28, 2026 | MORELAND, MARY K EXECUTIVE VICE PRESIDENT | Buy | 5,314 | $94.41 | $501,694.74 | - |
| Apr 27, 2026 | STARKS, DANIEL J Director | Buy | 10,000 | $92.65 | $926,537.00 | - |
| Apr 24, 2026 | ROMAN, MICHAEL F Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | STARKS, DANIEL J Director | Buy | 7,105 | $0.00 | $0.00 | - |
| Apr 24, 2026 | STARKS, DANIEL J Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | BLOUNT, SALLY E. Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | GONZALEZ, PATRICIA PAOLA Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | KUMBIER, MICHELLE Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | MCDEW, DARREN W Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | CONROY, KEVIN T Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | AHUJA, NITA Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | BABINEAUX-FONTENOT, CLAIRE Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | MCKINSTRY, NANCY Director | Buy | 2,305 | $0.00 | $0.00 | - |
| Apr 24, 2026 | MCKINSTRY, NANCY Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | O'GRADY, MICHAEL Director | Buy | 5,929 | $0.00 | $0.00 | - |
| Apr 24, 2026 | O'GRADY, MICHAEL Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 24, 2026 | STRATTON, JOHN G Director | Buy | 2,286 | $0.00 | $0.00 | - |
| Apr 23, 2026 | BOUDREAU, PHILIP P EVP AND CFO | Buy | 2,200 | $91.50 | $201,300.00 | - |
| Apr 23, 2026 | BOUDREAU, PHILIP P EVP AND CFO | Buy | 8,909 | $92.04 | $819,984.36 | - |
| Mar 31, 2026 | STRATTON, JOHN G Director | Buy | 382 | $102.67 | $39,219.94 | - |
| Mar 31, 2026 | ROMAN, MICHAEL F Director | Buy | 367 | $102.67 | $37,679.89 | - |
| Mar 31, 2026 | GONZALEZ, PATRICIA PAOLA Director | Buy | 321 | $102.67 | $32,957.07 | - |
| Mar 31, 2026 | ALPERN, ROBERT J Director | Buy | 76 | $102.67 | $7,802.92 | - |
| Mar 31, 2026 | AHUJA, NITA Director | Buy | 102 | $102.67 | $10,472.34 | - |
| Mar 23, 2026 | ORVILLE, JACOB A Senior Vice President | Buy | 13,255 | $0.00 | $0.00 | - |
| Mar 2, 2026 | MCCOY, JOHN A. JR. VICE PRESIDENT AND CONTROLLER | Sell | 585 | $115.58 | $67,614.30 | - |
| Mar 2, 2026 | SALVADORI, DANIEL GESUA SIVE EVP AND GROUP PRESIDENT | Sell | 885 | $115.58 | $102,288.30 | - |
| Mar 2, 2026 | SHROFF, ERIC Senior Vice President | Sell | 709 | $115.58 | $81,946.22 | - |
| Mar 2, 2026 | MORELAND, MARY K EXECUTIVE VICE PRESIDENT | Sell | 613 | $115.58 | $70,850.54 | - |
| Mar 2, 2026 | MORRONE, LOUIS H. EXECUTIVE VICE PRESIDENT | Sell | 1,144 | $115.58 | $132,223.52 | - |
| Mar 2, 2026 | CUSHMAN, ELIZABETH C. EVP, GC AND SECRETARY | Sell | 263 | $115.58 | $30,397.54 | - |
| Feb 27, 2026 | BOUDREAU, PHILIP P EVP AND CFO | Sell | 7,441 | $116.26 | $865,090.66 | - |
| Feb 27, 2026 | MCCOY, JOHN A. JR. VICE PRESIDENT AND CONTROLLER | Sell | 1,142 | $116.26 | $132,768.92 | - |
| Feb 27, 2026 | FORD, ROBERT B Director, CHAIRMAN AND CEO | Sell | 30,308 | $116.26 | $3.52M | - |
| Feb 27, 2026 | SALVADORI, DANIEL GESUA SIVE EVP AND GROUP PRESIDENT | Sell | 6,615 | $116.26 | $769,059.90 | - |
| Feb 27, 2026 | CUSHMAN, ELIZABETH C. EVP, GC AND SECRETARY | Sell | 1,421 | $116.26 | $165,205.46 | - |
| Feb 27, 2026 | MORELAND, MARY K EXECUTIVE VICE PRESIDENT | Sell | 4,630 | $116.26 | $538,283.80 | - |
| Feb 27, 2026 | MORRONE, LOUIS H. EXECUTIVE VICE PRESIDENT | Sell | 4,040 | $116.26 | $469,690.40 | - |
| Feb 27, 2026 | EARNHARDT, LISA D EVP AND GROUP PRESIDENT | Sell | 8,577 | $116.26 | $997,162.02 | - |
| Feb 27, 2026 | SCOGGINS, CHRISTOPHER J EXECUTIVE VICE PRESIDENT | Sell | 4,997 | $116.26 | $580,951.22 | - |
Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.
AI Stock Analysis
Unlock an in-depth, balanced bull/bear breakdown of ABT — catalysts, risks, and a plain-language read on the fundamentals.
Upgrade to PROInvestor Copilot Notebook
Keep a thesis on ABT
Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.
Upgrade to PROInvestment Thesis Timeline
See ABT's full timeline
Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.
Upgrade to PRODeeper technical charting, indicators, and pattern tools that complement XMarketPro's research.
Open advanced chartsSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
Automated technical analysis, charting, and pattern recognition for active traders.
Explore automated technical analysisSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
Another independent research perspective to compare against XMarketPro's own analysis.
Compare with additional researchSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
A well-established U.S. brokerage for investors moving from research into execution.
Explore brokerage optionsSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Visit abbott.comKey Statistics
- Open
- $112.25
- Prev Close
- $110.36
- Day High
- $113.85
- Day Low
- $109.10
- Volume
- 3.81M
- Market Cap
- $189.56B
- P/E Ratio
- 35.45
- EPS
- $3.09
- Beta
- 0.58
- Dividend Yield
- +2.28%
- 52W High
- $137.49
- 52W Low
- $81.97
- Analyst Target
- —